Funding for this research was provided by:
National Institutes of Health (DK114460)
National Institute of Diabetes and Digestive and Kidney Diseases (RO1-DK67071)
Received: 18 November 2021
Accepted: 13 June 2022
First Online: 26 July 2022
: All participants provided written informed consent for genotyping analysis and further utilization of their data as part of the Mayo Clinic Biobank and the RIGHT Study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Mayo Clinic Institutional Review Board (IRB 19–001222), formal consent was waived due to minimal risk.
: Not applicable.
: Dr. Andres Acosta is a stockholder in Gila Therapeutics and Phenomix Sciences; he serves as a consultant for Rhythm Pharmaceuticals, General Mills. Dr. Camilleri is a stockholder in Phenomix Sciences and Enterin and serves as a consultant to Takeda, Allergan, Kallyope, and Arena with compensation to his employer, Mayo Clinic. Drs. Sneha Singh, Maria L Ricardo-Silgado, Lizeth Cifuentes, Daniel Gonzalez-Izundegui, Maria Daniela Hurtado, Ann Moyer, and Suzette Bielinski have no disclosures.